Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib Colon Pathology in HER2+ Breast Cancer
NCT04366713Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neratinib in HER2-positive breast cancer, sponsored by Puma Biotechnology, Inc. Primary endpoint: Changes in Colon Pathology at 88 days. Started Jun 2020; status: completed.
02
Drugs
neratinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04366713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366713.